Exchange & Returns Information
Review Details
(26)
| Drug Type | Original |
|---|---|
| Active Ingredient | SEMAGLUTIDE |
| Strength | 0.25MG |
| Manufacturer | NOVO NORDISK |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 360.00 | $ 360.00 |
$ 302.40
Apply WEGO26 (-16%)
You save $ 57.60
|
||
| 2 BOXES - 2 PENS | $ 299.50 |
17% $ 720.00
$ 599.00
|
$ 503.16
Apply WEGO26 (-16%)
You save $ 95.84
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 253.00 |
30% $ 1,080.00
$ 759.00
|
$ 637.56
Apply WEGO26 (-16%)
You save $ 121.44
|
Reference information will be available soon.
Wegovy 0.25mg Flextouch Pen is a prefilled subcutaneous injection containing semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist indicated for chronic weight management in adults. By mimicking endogenous GLP-1, semaglutide modulates appetite regulation and delays gastric emptying, thereby enhancing satiety and reducing caloric intake. It also promotes insulin secretion and suppresses glucagon levels in a glucose-dependent manner. Though originally developed in the context of type 2 diabetes management, this specific formulation—Wegovy—is FDA-approved for obesity treatment and should not be considered a diabetes medication. Wegovy represents a paradigm shift in metabolic weight control by offering a non-stimulant, hormone-based alternative to traditional diet pills.
- DIET (Metabolic Weight Control) > As a long-acting GLP-1 agonist, Wegovy is approved for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related comorbidities. It helps reduce food cravings, prolong satiety, and supports sustainable fat loss when combined with dietary restriction and exercise. - DIABETES (GLP-1 Receptor Agonists) > Although semaglutide is commonly prescribed off-label for glucose modulation in type 2 diabetes, Wegovy itself does not carry this indication. In some clinical scenarios, subcutaneous semaglutide may be co-opted to assist glycemic control in patients with overlapping metabolic disorders, but this usage is off-label and should be medically supervised.
Semaglutide acts by binding to GLP-1 receptors, enhancing insulin secretion in a glucose-dependent manner while simultaneously suppressing glucagon release. This dual action helps lower blood sugar and reduce appetite. In the context of obesity, its primary effect is delaying gastric emptying and influencing hypothalamic satiety pathways, resulting in reduced food intake and improved long-term weight control. Unlike stimulant-based agents, semaglutide has no direct effect on the sympathetic nervous system, making it suitable for patients seeking a hormonal, non-thermogenic strategy for weight loss.
→ Chronic Weight Management Protocol (Wegovy-specific): - Week 1–4: 0.25 mg SC once weekly - Week 5–8: 0.5 mg SC once weekly - Week 9–12: 1.0 mg SC once weekly - Week 13–16: 1.7 mg SC once weekly - Week 17 and beyond: 2.4 mg SC once weekly (maintenance dose) → Dose Adjustments: - If not tolerated at any stage, delay the increase by an additional 4 weeks - If 2.4 mg is not tolerated, reduce to 1.7 mg weekly for up to 4 weeks and then attempt to resume 2.4 mg - Discontinue if 2.4 mg remains intolerable → Key Use Criteria: - Adults with BMI ≥30 kg/m² (obesity), or - Adults with BMI ≥27 kg/m² and one or more weight-related comorbidities (e.g., hypertension, dyslipidemia, type 2 diabetes) → Important Notes: - Must be combined with a reduced-calorie diet and increased physical activity - Not to be used concurrently with other GLP-1 receptor agonists or semaglutide-containing drugs - Not studied in patients with active or prior pancreatitis → Off-Label Use (Not Wegovy-specific): - Type 2 diabetes control: Initial 0.25 mg/week → titrate to 0.5–1.0 mg/week as tolerated - Switching from oral semaglutide (14 mg) to SC: begin 0.5 mg SC after last oral dose - Max dose for off-label glycemic use: 1 mg/week
Store in a refrigerator at 2–8°C. Do not freeze. Keep pens in their original packaging to protect from light. Once in use, pens may be kept at room temperature (below 30°C) for up to 28 days. Keep out of reach of children.
Most common side effects include nausea, vomiting, diarrhea, abdominal discomfort, and constipation. These effects are typically transient and diminish as the body adapts to higher doses. Serious adverse events may include pancreatitis, gallbladder disease, or renal impairment. Hypoglycemia risk is low when used alone but increases when combined with insulin or sulfonylureas. Seek immediate medical attention for signs of severe abdominal pain, persistent vomiting, or vision disturbances.
The cold-pack packaging worked perfectly. The pen was still cool when I opened the box.
I was very anxious about my first order, especially regarding the refrigerated shipping. I contacted customer service with a list of questions, and the representative, Sarah, was incredibly patient and thorough. She explained the entire cold-chain process, what to expect upon delivery, and how to store the pen. Her professionalism completely put my mind at ease. The Wegovy pen arrived exactly as she described. This level of care and support is why I'll be a loyal customer.
I was a bit nervous about the injection, but the pen is designed so well it was completely painless and simple.
Mein Wegovy 0,25mg Pen kam pünktlich und gut gekühlt an. Der Bestellvorgang war unkompliziert. Ein zuverlässiger Anbieter.
Good experience all around. No reason to go anywhere else.
No combo deals available at the moment.
